Molecular activators of PP2A enhance the anti-inflammatory function of TTP in lung cancer cells, and thus, provide pharmacotherapeutic strategies to chronic inflammation-mediated cancer [133]. This evidence concerns the gene ZFP36 and lung carcinoma.